DGIdb - FCGR3B Gene Record

FCGR3B 2215 Druggable Genome

Alternate Names:

2215
FC FRAGMENT OF IGG RECEPTOR IIIB
FCGR3B
CD16
CD16b
FCG3
FCGR3
FCR-10
FCRIII
FCRIIIb
610665
3620
ENSG00000162747
OTTHUMG00000074099
BE0000901
O75015

Gene Info:

Gene Biotype	PROTEIN_CODING

(0 More Sources)

Gene Categories: Category Details

DRUGGABLE GENOME

Publications:

Snyder et al., 2005, Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer., Clin Colorectal Cancer
Fujita et al., 2007, Successful treatment of primary Sjögren's syndrome with chronic natural killer lymphocytosis by high-dose prednisolone and indomethacin farnesil., Intern. Med.
Harris et al., 1989, Induction of activation antigens on human natural killer cells mediated through the Fc-gamma receptor., J. Immunol.
Smyth et al., 1991, IL-8 gene expression and production in human peripheral blood lymphocyte subsets., J. Immunol.
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Hiatt A et al., 2014, Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy., Proc Natl Acad Sci U S A
Contasta et al., 1996, Necessity of biotherapeutic treatments inducing TH1 cell functions in colorectal cancer., Cancer Biother. Radiopharm.
Pellegrini et al., 1996, Immunological directives for biotherapy improvement in the treatment of colorectal cancer., Cancer Biother. Radiopharm.
Bossowski et al., 2003, Analysis of circulating T gamma/delta lymphocytes and CD16/56 cell populations in children and adolescents with Graves' disease., Pediatr. Res.
Schlenzka et al., 2004, Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma., Anticancer Drugs
Yeager et al., 2002, Intravenous fentanyl increases natural killer cell cytotoxicity and circulating CD16(+) lymphocytes in humans., Anesth. Analg.
Maes et al., 2007, Comparison of sample fixation and the use of LDS-751 or anti-CD45 for leukocyte identification in mouse whole blood for flow cytometry., J. Immunol. Methods
Indraccolo et al., 1993, Standardization of in vitro synthesis and detection of HIV-1-specific antibodies., J. Immunol. Methods
Baj et al., 1992, T lymphocyte subsets and NK cell cytotoxicity in chronic hemodialysis patients. The effect of recombinant human erythropoietin (rHu-EPO) treatment., Arch. Immunol. Ther. Exp. (Warsz.)
Osterborg et al., 1997, Clonal CD8+ and CD52- T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52)., Eur. J. Haematol.
Nagler et al., 1997, Enhancement of megakaryocytopoiesis by Campath-1G-treated natural killer cells., Bone Marrow Transplant.
Brett et al., 1996, Repopulation of blood lymphocyte sub-populations in rheumatoid arthritis patients treated with the depleting humanized monoclonal antibody, CAMPATH-1H., Immunology
Baran et al., 2007, Upregulation of multi drug resistance genes in doxorubicin resistant human acute myelogeneous leukemia cells and reversal of the resistance., Hematology
Lanier et al., 1985, Functional properties of a unique subset of cytotoxic CD3+ T lymphocytes that express Fc receptors for IgG (CD16/Leu-11 antigen)., J. Exp. Med.
Hayakawa et al., 1991, The role of IL-4 in proliferation and differentiation of human natural killer cells. Study of an IL-4-dependent versus an IL-2-dependent natural killer cell clone., J. Immunol.
Hoshino et al., 1991, Activation via the CD3 and CD16 pathway mediates interleukin-2-dependent autocrine proliferation of granular lymphocytes in patients with granular lymphocyte proliferative disorders., Blood
Galandrini et al., 1993, Antibodies to CD44 trigger effector functions of human T cell clones., J. Immunol.
Martelletti et al., 1990, Defective expression of IL-2 receptors on peripheral blood lymphocytes from patients with cluster headache., Headache
Ozgocmen et al., 2007, Acute-phase response, clinical measures and disease activity in ankylosing spondylitis., Joint Bone Spine
Hart et al., 2000, Molecular characterization of the surface of apoptotic neutrophils: implications for functional downregulation and recognition by phagocytes., Cell Death Differ.
Criswell et al., 2004, The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept., Arthritis Rheum.
Hughes et al., 2004, Genetic risk factors for infection in patients with early rheumatoid arthritis., Genes Immun.
Arora T et al., 2009, Differences in binding and effector functions between classes of TNF antagonists., Cytokine
Schomburg et al., 1992, Biologic and therapeutic efficacy of mafosfamide in patients with metastatic renal cell carcinoma., Mol. Biother.
Ordi et al., 2006, Uterine (CD56+) natural killer cells recruitment: association with decidual reaction rather than embryo implantation., Am. J. Reprod. Immunol.
Seitz et al., 1998, Effects of methotrexate on differentiation of monocytes and production of cytokine inhibitors by monocytes., Arthritis Rheum.
Weber F et al., 2018, First Infusion Reactions are Mediated by FcγRIIIb and Neutrophils., Pharm Res
Takahashi et al., 2007, Induction of CD16+ CD56bright NK cells with antitumour cytotoxicity not only from CD16- CD56bright NK Cells but also from CD16- CD56dim NK cells., Scand. J. Immunol.
Paciucci et al., 1991, Immunotherapy with IL2 by constant infusion and weekly doxorubicin., Am. J. Clin. Oncol.
Mathison et al., 2008, The tripeptide feG inhibits leukocyte adhesion., J Inflamm (Lond)
Vendemiale et al., 1992, Crystalline lactulose in the therapy of hepatic cirrhosis. Evaluation of clinical and immunological parameters. Preliminary results., Arzneimittelforschung
da Silva et al., 2002, Alefacept, an immunomodulatory recombinant LFA-3/IgG1 fusion protein, induces CD16 signaling and CD2/CD16-dependent apoptosis of CD2(+) cells., J. Immunol.
Edwards et al., 1995, Evidence for a dithiol-activated signaling pathway in natural killer cell avidity regulation of leukocyte function antigen-1: structural requirements and relationship to phorbol ester- and CD16-triggered pathways., Blood
Seimetz D et al., 2010, Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy., Cancer Treat Rev

NATALIZUMAB FCGR3B

Interaction Score: 1.31

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17016423 17139284 29951887

Sources:
DrugBank
MUROMONAB-CD3 FCGR3B

Interaction Score: 1.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10851498 10851527

Sources:
DrugBank
ALEFACEPT FCGR3B

Interaction Score: 0.98

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11970990

Sources:
DrugBank
LACTULOSE FCGR3B

Interaction Score: 0.98

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1418064

Sources:
NCI
MAFOSFAMIDE FCGR3B

Interaction Score: 0.98

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1515095

Sources:
NCI
ALEMTUZUMAB FCGR3B

Interaction Score: 0.98

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9020367 9337053 8707338

Sources:
DrugBank
PALIVIZUMAB FCGR3B

Interaction Score: 0.98

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17016423 17139284 24711420

Sources:
DrugBank
DACLIZUMAB FCGR3B

Interaction Score: 0.84

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2415663 1900882 1835892 8097750 2335478

Sources:
DrugBank
PENICILLIN G POTASSIUM FCGR3B

Interaction Score: 0.78

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17257217

Sources:
NCI
CATUMAXOMAB FCGR3B

Interaction Score: 0.49

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

PMIDs:
20347527

Sources:
DrugBank
ETANERCEPT FCGR3B

Interaction Score: 0.47

Interaction Types & Directionality:

ligand

Interaction Info:

PMIDs:
17387033 10800083 15457442 15526004 19128982

Sources:
DrugBank
SARILUMAB FCGR3B

Interaction Score: 0.33

Interaction Types & Directionality:

other/unknown

Interaction Info:

PMIDs:
None found

Sources:
DrugBank
CHOLECALCIFEROL FCGR3B

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9811059

Sources:
NCI
SODIUM CHLORIDE FCGR3B

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17187818

Sources:
NCI
GELDANAMYCIN FCGR3B

Interaction Score: 0.26

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
7662976

Sources:
NCI
ALDESLEUKIN FCGR3B

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
2528593 1827816

Sources:
NCI
METHIMAZOLE FCGR3B

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12761360

Sources:
NCI
EPOETIN ALFA FCGR3B

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1300984

Sources:
NCI
PUROMYCIN FCGR3B

Interaction Score: 0.2

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
8423352

Sources:
NCI
FENTANYL FCGR3B

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11772808

Sources:
NCI
PREDNISOLONE FCGR3B

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17329922

Sources:
NCI
THALIDOMIDE FCGR3B

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15457133

Sources:
NCI
HEPARIN FCGR3B

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
18492254

Sources:
NCI
INDOMETHACIN FCGR3B

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17329922

Sources:
NCI
CETUXIMAB FCGR3B

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16336752

Sources:
DrugBank
CYCLOSPORINE FCGR3B

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17852453

Sources:
NCI
PROGESTERONE FCGR3B

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16635211

Sources:
NCI
DOXORUBICIN FCGR3B

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
1830717

Sources:
NCI
METHOTREXATE FCGR3B

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
9811059

Sources:
NCI

Ensembl: ENSG00000162747
- Version: 101_38
Alternate Names:

FCGR3B Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:

DrugBank: BE0000901

Version: 5.1.7

Alternate Names:

FCGR3B DrugBank Gene Name

O75015 UniProt Accession

2215 Entrez Gene Id

Gene Info:

Publications:

Snyder et al., 2005, Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer., Clin Colorectal Cancer

Arora T et al., 2009, Differences in binding and effector functions between classes of TNF antagonists., Cytokine

Criswell et al., 2004, The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept., Arthritis Rheum.

NCI: FCGR3B

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

Smyth et al., 1991, IL-8 gene expression and production in human peripheral blood lymphocyte subsets., J. Immunol.

Harris et al., 1989, Induction of activation antigens on human natural killer cells mediated through the Fc-gamma receptor., J. Immunol.

Schlenzka et al., 2004, Combined effect of recombinant CD19 x CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma., Anticancer Drugs

HingoraniCasas: ENSG00000162747
- Version: 31-May-2017
Alternate Names:

ENSG00000162747 Gene Symbol

FCGR3B Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:

FCGR3B	DrugBank Gene Name
O75015	UniProt Accession
2215	Entrez Gene Id

FCGR3B Gene Record

FCGR3B 2215 Druggable Genome

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17016423 17139284 29951887

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10851498 10851527

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11970990

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 1418064

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 1515095

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9020367 9337053 8707338

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17016423 17139284 24711420

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 2415663 1900882 1835892 8097750 2335478

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17257217

Sources: NCI

Interaction Types & Directionality: agonist (activating)

Interaction Info:

PMIDs: 20347527

Sources: DrugBank

Interaction Types & Directionality: ligand

Interaction Info:

PMIDs: 17387033 10800083 15457442 15526004 19128982

Sources: DrugBank

Interaction Types & Directionality: other/unknown

Interaction Info:

PMIDs: None found

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 9811059

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17187818

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 7662976

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 2528593 1827816

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12761360

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 1300984

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

n/a

PMIDs:
17016423 17139284 29951887

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
10851498 10851527

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
11970990

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
1418064

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
1515095

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
9020367 9337053 8707338

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
17016423 17139284 24711420

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
2415663 1900882 1835892 8097750 2335478

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
17257217

Sources:
NCI

Interaction Types & Directionality:

agonist (activating)

PMIDs:
20347527

Sources:
DrugBank

Interaction Types & Directionality:

ligand

PMIDs:
17387033 10800083 15457442 15526004 19128982

Sources:
DrugBank

Interaction Types & Directionality:

other/unknown

PMIDs:
None found

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
9811059

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17187818

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
7662976

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
2528593 1827816

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12761360

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
1300984

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
8423352

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11772808

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17329922

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15457133

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
18492254

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17329922

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16336752

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
17852453

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16635211